Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03651271
Title Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Parker Institute for Cancer Immunotherapy
Indications

Advanced Solid Tumor

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.